Literature DB >> 28197902

Neuropsychiatric Effects of Antimicrobial Agents.

Nicholas Zareifopoulos1, George Panayiotakopoulos2.   

Abstract

Antimicrobial drugs used in clinical practice are selected on the basis of their selective toxicity against bacterial cells. However, all exhibit multiple offsite interactions with eukaryotic cell structures, resulting in adverse reactions during antimicrobial pharmacotherapy. A multitude of these side effects involve the nervous system as antimicrobials at clinically relevant concentrations seem to interact with many of the same molecules usually implicated in the action of psychotropic drugs. The importance of such events cannot be overstated, as the misdiagnosis of an adverse drug reaction as a symptom of a primary psychiatric or neurological disorder entails great suffering for the patient affected as well as significant costs for the healthcare system. The neuropsychiatric effects of antimicrobial drugs are extensively documented in the literature. A number of antimicrobial drugs have the potential to exert CNS effects and many are associated with stimulant, psychotomimetic and epileptogenic properties, mediated by GABA antagonism (beta-lactams, quinolones and clarithromycin), NMDA agonism (D-cycloserine, aminoglycosides, and perhaps quinolones), MAO inhibition (linezolid, metronidazole and isoniazid weakly) as well as more exotic mechanisms, as in the case of trimethoprim, isoniazid, ethambutol, rifampicin and the tetracyclines. While those effects are generally undesirable, they may also under certain circumstances be beneficial, and further research is warranted in that direction.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28197902     DOI: 10.1007/s40261-017-0498-z

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  145 in total

1.  A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii.

Authors:  Faith B Dickerson; Cassie R Stallings; John J Boronow; Andrea E Origoni; Robert H Yolken
Journal:  Schizophr Res       Date:  2009-05-23       Impact factor: 4.939

2.  Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia.

Authors:  Ying-Jui Ho; Shih-Chun Ho; Cornelius Rainer Pawlak; Kuei-Ying Yeh
Journal:  Behav Brain Res       Date:  2011-01-22       Impact factor: 3.332

3.  Further experience using clarithromycin in patients with Kleine-Levin syndrome.

Authors:  Lynn Marie Trotti; Donald L Bliwise; David B Rye
Journal:  J Clin Sleep Med       Date:  2014-04-15       Impact factor: 4.062

4.  Cycloserine Induced Late Onset Psychosis and Ethambutol Induced Peripheral Neuropathy Associated with MDR-TB Treatment in an Indian Patient- A Rare Case Report.

Authors:  Sadhana Holla; Mohan Babu Amberkar; Rajeshkrishna Bhandarypanambur; Meenakumari Kamalkishore; Manju Janardhanan
Journal:  J Clin Diagn Res       Date:  2015-02-01

5.  Anxiolytic-like effect of linezolid in experimental mouse models of anxiety.

Authors:  Ankur Jindal; Radhakrishnan Mahesh; Baldev Kumar
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-09-25       Impact factor: 5.067

6.  Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats.

Authors:  S Marchand; C Pariat; S Bouquet; P Courtois; W Couet
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

7.  Successful treatment of ventriculostomy-associated meningitis caused by multidrug resistant coagulase-negative Staphylococcus epidermidis using low-volume intrathecal daptomycin and loading strategy.

Authors:  Tina Harrach Denetclaw; Ion Suehiro; Phyllis K Wang; Gregg L Tolliver
Journal:  Ann Pharmacother       Date:  2014-07-03       Impact factor: 3.154

8.  A ketolide antibiotic, telithromycin, inhibits vascular adrenergic neurotransmission in the rat mesenteric vascular bed.

Authors:  Y Hatanaka; Y Zamami; T Koyama; N Hobara; X Jin; Y Kitamura; H Kawasaki
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

9.  Possible intermolecular interaction between quinolones and biphenylacetic acid inhibits gamma-aminobutyric acid receptor sites.

Authors:  K Akahane; Y Kimura; Y Tsutomi; I Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Ofloxacin-induced hallucinations.

Authors:  Urmila Chauhan; Preeti Shanbag; Prafull Kashid
Journal:  Indian J Pharmacol       Date:  2013 Mar-Apr       Impact factor: 1.200

View more
  5 in total

1.  Delirium induced by tigecycline treatment for Acinetobacter baumannii infection: A case report.

Authors:  Xiaoying Zheng; Huiming Jiang; Lifen Xue; Feng Qiu; Shenyin Zhu; Xinyu Li
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

2.  Doxycycline exposure during adolescence and future risk of non-affective psychosis and bipolar disorder: a total population cohort study.

Authors:  Fredrik Upmark; Hugo Sjöqvist; Joseph F Hayes; Christina Dalman; Håkan Karlsson
Journal:  Transl Psychiatry       Date:  2021-09-08       Impact factor: 6.222

3.  A VigiBase Descriptive Study of Fluoroquinolone-Associated Peripheral Nervous System Disorders.

Authors:  Madalina Huruba; Andreea Farcas; Daniel Corneliu Leucuta; Camelia Bucsa; Cristina Mogosan
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-26

Review 4.  Antibiotics and the Nervous System-Which Face of Antibiotic Therapy Is Real, Dr. Jekyll (Neurotoxicity) or Mr. Hyde (Neuroprotection)?

Authors:  Magdalena Hurkacz; Lukasz Dobrek; Anna Wiela-Hojeńska
Journal:  Molecules       Date:  2021-12-09       Impact factor: 4.411

5.  Macrolide-associated ototoxicity: a cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and hearing loss.

Authors:  Anna Vanoverschelde; Berthe C Oosterloo; Nelly F Ly; M Arfan Ikram; André Goedegebure; Bruno H Stricker; Lies Lahousse
Journal:  J Antimicrob Chemother       Date:  2021-09-15       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.